PROCESSING CRYOPRESERVED HUMAN SPERM

处理冷冻保存的人类精子

• 批准号: 6796016
• 负责人: ROY H HAMMERSTEDT
• 金额: $ 22.66万
• 依托单位: APD LIFE SCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2005-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6796016
• 关键词: biomedical automation; cell membrane; cell osmotic pressure; clinical biomedical equipment; cryopreservation; cryoprotective agents; cytotoxicity; heat injury; human tissue; male; physical separation; sperm; technology /technique development; tissue /cell preparation

DESCRIPTION (Scanned from the applicant's description): Cryopreserved human sperm are essential for important therapies. With standard procedures, post-thaw quality of samples from many/most patients (donors are highly selected) is unacceptable, 40 percent of the sperm are damaged, and pregnancy rate is low. Biology to improve outcome is available, but unused because of limited efforts to adapt knowledge to an approach practical in a clinical setting. This project is focused on that goal and will use containers with "gated-pore" faces and a "rapid cryoprotectant removal device" (RCRD) to eliminate post-thaw damage to human sperm resulting from rapid movement of water into the cells. Their use allows cryopreservation of sperm within a sealed container, and post-thaw opening of the gated pores and, at a rate safe for the sperm, replacement of cryo-extender with a buffer appropriate for intrauterine insemination (IUI) and not irritating to tissues--automatically and safely (for sperm and operator) without dilution or removal of sperm from the container until IUI. Phase-I demonstrated feasibility. Phase-II objectives are: (1) refine the CryoCell container and RCRD to meet standards needed for clinical trials and optimize thaw rate; (2) compare results with the new technology and standard procedures; and (3) evolve and validate procedures appropriate for clinical trials. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（根据申请人描述扫描）：冻存人 精子是重要治疗所必需的。按照标准程序， 来自许多/大多数患者的样品的解冻后质量（供体是高度 选择）是不可接受的，40%的精子受损，怀孕 率低。改善结果的生物学是可用的，但由于 将知识应用于临床实践方法的努力有限 设置.这个项目的重点是这一目标，并将使用容器与 “门孔”面和“快速冷冻保护剂去除装置”（RCRD）， 消除解冻后由于快速运动而对人类精子造成的损害， 水进入细胞。它们的使用允许在一个特定的时间内冷冻保存精子。 密封容器，解冻后打开门控孔， 对于精子，用适合于冷冻的缓冲液代替冷冻稀释液， 子宫内人工授精（IUI）和不刺激组织-自动 安全（对于精子和操作者），无需稀释或去除精子， 容器直到IUI。第一阶段证明了可行性。第二阶段目标 （1）改进CryoCell容器和RCRD，以满足 临床试验和优化解冻速率;（2）将结果与新的 技术和标准程序;（3）发展和验证程序 适合临床试验。 拟议商业应用：不可用

项目成果

Commercialization of basic research from within the university and return of value to the public.

大学内部基础研究的商业化以及向公众的价值回报。

• DOI: 10.1016/j.anireprosci.2007.11.014
• 发表时间: 2008
• 期刊: Animal reproduction science
• 影响因子: 2.2
• 作者: Hammerstedt,RoyH;Blach,EdwardL
• 通讯作者: Blach,EdwardL